C
Claudia Palena
Researcher at National Institutes of Health
Publications - 110
Citations - 5462
Claudia Palena is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Brachyury & Immunotherapy. The author has an hindex of 35, co-authored 102 publications receiving 4279 citations. Previous affiliations of Claudia Palena include Office of Technology Transfer.
Papers
More filters
Journal ArticleDOI
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes
Charlie T. Garnett,Claudia Palena,Mala Chakarborty,Kwong-Yok Tsang,Jeffrey Schlom,James W. Hodge +5 more
TL;DR: The results of this study suggest that nonlethal doses of radiation can be used to make human tumors more amenable to immune system recognition and attack and form the rational basis for the combinatorial use of cancer vaccines and local tumor irradiation.
Journal ArticleDOI
IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells
TL;DR: The results emphasize the potential role of EMT in the modulation of the tumor microenvironment via secretion of multiple soluble mediators and suggest that IL-8 signaling blockade may provide a means of targeting mesenchymal-like, invasive tumor cells.
Journal ArticleDOI
The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance
TL;DR: The dual potential roles that the inflammatory cytokine IL-8 plays in promoting tumor resistance by enhancing the immunosuppressive microenvironment and activating EMT are highlighted, and the potential for targeting the IL- 8/IL-8 receptor axis to combat these various resistance mechanisms is discussed.
Journal ArticleDOI
The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells
Romaine I. Fernando,Mary T. Litzinger,Paola Trono,Duane H. Hamilton,Jeffrey Schlom,Claudia Palena +5 more
TL;DR: Overexpression of Brachyury in human carcinoma cells induced changes characteristic of EMT, including upregulation of mesenchymal markers, downregulation of epithelial markers, and an increase in cell migration and invasion.
Journal ArticleDOI
Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma
James L. Gulley,Philip M. Arlen,Kwong-Yok Tsang,Junko Yokokawa,Claudia Palena,Diane J. Poole,Cinzia Remondo,Vittore Cereda,Jacquin Jones,Mary Pazdur,Jack P. Higgins,James W. Hodge,Seth M. Steinberg,Herbert L. Kotz,William L. Dahut,Jeffrey Schlom +15 more
TL;DR: This poxviral vaccine strategy seems to be safe, is associated with both CD8 and CD4 immune responses, and has shown evidence of clinical activity.